Cholestatic Hepatitis Associated With Repaglinide
- Francisco López-García, MD1,
- Joaquín Borrás, PHARMD, PHD2,
- Clara Verdú, MD, PHD3,
- V.R. Salazar, MD4,
- J. Antonio Ruiz, MD5,
- Jorge Sales, MD, PHD6,
- Mª Isabel Lucena, MD, PHD7 and
- Raúl J. Andrade, MD, PHD8
- 1Department of Internal Medicine, Hospital Orihuela, Alicante, Spain
- 2Pharmacy Service, Hospital Elche, Alicante, Spain
- 3Gastroenterology and Hepatology Service, Hospital Orihuela, Alicante, Spain
- 4Department of Internal Medicine, Hospital Orihuela, Alicante, Spain
- 5Pathology Service, Hospital Orihuela, Alicante, Spain
- 6Endocrinology Service, Hospital Orihuela, Alicante, Spain
- 7Clinical Pharmacology Service, Hospital de Málaga, Málaga, Spain
- 8Liver Unit, Gastroenterology Service, University Hospital, School of Medicine, Málaga, Spain
- Address correspondence to Francisco López-García, MD, Department of Internal Medicine, Hospital Orihuela, Alicante, Maestro Alonso n° 100-1° piso, 03012 Alicante, Spain. E-mail: f.lopezgarcia{at}terra.es
Repaglinide is a fast, short-acting meglitinide analog antidiabetic drug approved for the treatment of type 2 diabetes. Hypoglycemia is a major adverse effect of this drug (1). In rare cases, elevated liver enzymes have been noted (2). We report a patient who developed cholestatic hepatitis while taking repaglinide.
A 72-year-old man had a 2-year history of type 2 diabetes that was initially controlled by diet. He had normal liver function. Two months before presentation, he began taking repaglinide (1 mg/day), and 1 month before presentation, the daily dose was increased to 2 mg. The patient presented because of a 2-week history …
